<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and latency has been associated with malignant diseases including nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>, Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:hpo ids='HP_0002721'>immune deficiency</z:hpo> associated <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>EBV-encoded latent membrane protein 2A (LMP2A) recruits Lyn and Syk kinases via its SH2-domain binding motifs, and modifies their signaling pathways </plain></SENT>
<SENT sid="2" pm="."><plain>LMP2A transgenic mice develop hyperproliferative bone marrow B cells and immature peripheral B cells through modulation of Lyn kinase signaling </plain></SENT>
<SENT sid="3" pm="."><plain>LMP2A/Î»-MYC double transgenic mice develop <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> and cervical <z:hpo ids='HP_0002665'>lymphomas</z:hpo> starting at 8 weeks of age </plain></SENT>
<SENT sid="4" pm="."><plain>We reasoned that targeting Lyn in LMP2A-expressing B cells with <z:chebi fb="0" ids="49375">dasatinib</z:chebi> would provide a therapeutic option for EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Here, we show that <z:chebi fb="0" ids="49375">dasatinib</z:chebi> inhibits B cell colony formation by LMP2A transgenic bone marrow cells, and reverses <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in both a pre-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and a syngeneic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> transfer model of EBV-associated Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Our data support the idea that <z:chebi fb="0" ids="49375">dasatinib</z:chebi> may prove to be an effective therapeutic molecule for the treatment of EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>